Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Yifeng Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2765-8529; OpenAlex author ID A5101511145, A5104557251. Sources: OpenAlex.

Their work

Papers
18 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 3 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 18

  1. Hypertemperature-Detonated Biomimetic Semiconductor Stromal Bombs for Enhanced Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1002/adma.202523468↗
  2. Radical Antegrade Modular Pancreatosplenectomy Versus Standard Resection in T3 Body and Tail Pancreatic Ductal Adenocarcinoma: A Multicenter Retrospective Coho… Co-author DOI 10.1245/s10434-026-20627-y↗
  3. ASO Visual Abstract: Radical Antegrade Modular Pancreatosplenectomy Versus Standard Resection in T3 Body and Tail Pancreatic Ductal Adenocarcinoma: A Multicent… Co-author DOI 10.1245/s10434-026-20755-5↗
  4. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202508431↗
  5. Targeting the MCP-GPX4/HMGB1 Axis for Effectively Triggering Immunogenic Ferroptosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202308208↗
  6. miR-24-3p Regulates Epithelial-Mesenchymal Transition and the Malignant Phenotype of Pancreatic Adenocarcinoma by Regulating ASF1B Expression. Co-author DOI 10.1007/s10528-022-10278-5↗
  7. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Co-author DOI 10.1016/j.celrep.2022.110813↗
  8. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-022-02343-z↗
  9. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2021.01.010↗
  10. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s13045-021-01072-8↗
  11. Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer… Co-author DOI 10.3389/fonc.2021.646082↗
  12. Anterior gradient 2 is a novel pro-tumor factor in pancreatic cancer under NF-κB subunit RelA trans-regulation that can be suppressed by eugenic acid. Co-author DOI 10.1016/j.biopha.2020.110830↗
  13. LncRNA STXBP5-AS1 suppresses stem cell-like properties of pancreatic cancer by epigenetically inhibiting neighboring androglobin gene expression. Last author DOI 10.1186/s13148-020-00961-y↗
  14. SHCBP1 interacting with EOGT enhanced O-GlcNAcylation of NOTCH1 and promoted the development of pancreatic cancer . Co-author DOI 10.21203/rs.3.rs-95104/v1↗
  15. Silencing of long noncoding RNA LINC00958 prevents tumor initiation of pancreatic cancer by acting as a sponge of microRNA-330-5p to down-regulate PAX8. Co-author DOI 10.1016/j.canlet.2018.12.017↗
  16. RER1 enhances carcinogenesis and stemness of pancreatic cancer under hypoxic environment. Last author DOI 10.1186/s13046-018-0986-x↗
  17. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: … Co-author DOI 10.1016/j.ijbiomac.2017.03.123↗
  18. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice. Co-author DOI 10.1016/j.canlet.2016.09.027↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shi Chen · 14 shared papers, 2016–2026 · strength 1.76
  2. Cheng‐Yu Liao · 9 shared papers, 2020–2026 · strength 1.34
  3. Zuwei Wang · 7 shared papers, 2020–2025 · strength 0.99
  4. Long Huang · 9 shared papers, 2016–2022 · strength 0.97
  5. Can Yang · 7 shared papers, 2020–2022 · strength 0.80
  6. Baiyong Shen · 6 shared papers, 2019–2022 · strength 0.64
  7. Xiaowu Xu · 2 shared papers, 2026 · strength 0.60
  8. Dihang Wu · 2 shared papers, 2026 · strength 0.60
  9. Jianlin Lai · 2 shared papers, 2026 · strength 0.60
  10. Ge Li · 4 shared papers, 2020–2025 · strength 0.52
  11. Jiangzhi Chen · 4 shared papers, 2019–2024 · strength 0.49
  12. Yanling Chen · 4 shared papers, 2017–2024 · strength 0.47
  13. Qian Zhan · 4 shared papers, 2020–2021 · strength 0.45
  14. Yaodong Wang · 3 shared papers, 2021–2023 · strength 0.44
  15. Shun‐Cang Zhu · 2 shared papers, 2024–2025 · strength 0.38
  16. Yao-Dong Wang · 4 shared papers, 2017–2020 · strength 0.37
  17. Shi Chen · 1 shared paper, 2026 · strength 0.30
  18. Shi Chen · 1 shared paper, 2026 · strength 0.30
  19. Huixing Chen · 3 shared papers, 2017–2019 · strength 0.25
  20. Chenghong Peng · 3 shared papers, 2017–2019 · strength 0.25
  21. Chengke Xie · 1 shared paper, 2026 · strength 0.22
  22. Haoxiang Zhang · 1 shared paper, 2025 · strength 0.20
  23. Yu Pan · 1 shared paper, 2025 · strength 0.20
  24. Yongding Wu · 1 shared paper, 2025 · strength 0.20
  25. Wentao Huang · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.